These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9665302

  • 21. In vitro activity of HMR 3647 against anaerobic bacteria.
    Edlund C, Sillerström E, Wahlund E, Nord CE.
    J Chemother; 1998 Aug; 10(4):280-4. PubMed ID: 9720465
    [Abstract] [Full Text] [Related]

  • 22. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
    Behra-Miellet J, Dubreuil L, Jumas-Bilak E.
    Int J Antimicrob Agents; 2002 Nov; 20(5):366-74. PubMed ID: 12431872
    [Abstract] [Full Text] [Related]

  • 23. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
    Goldstein EJ, Citron DM, Hudspeth M, Hunt Gerardo S, Merriam CV.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1552-7. PubMed ID: 9210683
    [Abstract] [Full Text] [Related]

  • 24. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B, Naden M.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [Abstract] [Full Text] [Related]

  • 25. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
    Goldstein EJ, Citron DM, Warren Y, Tyrrell K, Merriam CV.
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
    [Abstract] [Full Text] [Related]

  • 26. Susceptibility of anaerobic bacteria to tosufloxacin.
    Nord CE, Lindmark A, Persson I, Runow C.
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
    [Abstract] [Full Text] [Related]

  • 27. In vitro activities of three of the newer quinolones against anaerobic bacteria.
    Wexler HM, Molitoris E, Finegold SM.
    Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
    [Abstract] [Full Text] [Related]

  • 28. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections.
    Milazzo I, Blandino G, Musumeci R, Nicoletti G, Lo Bue AM, Speciale A.
    Int J Antimicrob Agents; 2002 Dec; 20(6):451-6. PubMed ID: 12458140
    [Abstract] [Full Text] [Related]

  • 29. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
    Speciale A, Musumeci R, Blandino G, Milazzo I, Caccamo F, Nicoletti G.
    Int J Antimicrob Agents; 2002 Feb; 19(2):111-8. PubMed ID: 11850163
    [Abstract] [Full Text] [Related]

  • 30. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.
    Snydman DR, Jacobus NV, McDermott LA.
    Antimicrob Agents Chemother; 2011 Jan; 55(1):421-5. PubMed ID: 21041506
    [Abstract] [Full Text] [Related]

  • 31. Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals.
    Goldstein EJ, Citron DM.
    Antimicrob Agents Chemother; 1985 Feb; 27(2):162-6. PubMed ID: 3985600
    [Abstract] [Full Text] [Related]

  • 32. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM, Molitoris E, Reeves D, Finegold SM.
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
    [Abstract] [Full Text] [Related]

  • 33. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
    Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, Chong Y.
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.
    Hecht DW, Osmolski JR.
    Antimicrob Agents Chemother; 2003 Mar; 47(3):910-6. PubMed ID: 12604521
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Susceptibility of anaerobic bacteria in Auckland: 1991-1996.
    Shore KP, Pottumarthy S, Morris AJ.
    N Z Med J; 1999 Nov 12; 112(1099):424-6. PubMed ID: 10678225
    [Abstract] [Full Text] [Related]

  • 40. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE, Olsson-Liljequist B.
    Scand J Infect Dis Suppl; 1984 Nov 12; 43():44-9. PubMed ID: 6100139
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.